Your browser doesn't support javascript.
loading
Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale.
Roux, Paul; Urbach, Mathieu; Fonteneau, Sandrine; Berna, Fabrice; Brunel, Lore; Capdevielle, Delphine; Chereau, Isabelle; Dubreucq, Julien; Faget-Agius, Catherine; Fond, Guillaume; Leignier, Sylvain; Perier, Claire-Cécile; Richieri, Raphaëlle; Schneider, Priscille; Schürhoff, Franck; Tronche, Anne Marie; Yazbek, Hanan; Zinetti-Bertschy, Anna; Passerieux, Christine; Brunet-Gouet, Eric.
Affiliation
  • Roux P; 1 Fondation FondaMental, Créteil, France.
  • Urbach M; 2 Department of Adult Psychiatry, Versailles Hospital, Le Chesnay, France.
  • Fonteneau S; 3 HandiRESP Laboratory, EA4047, Health Sciences Department Simone Veil, University of Versailles Saint-Quentin-En-Yvelines, Montigny-le-Bretonneux, France.
  • Berna F; 1 Fondation FondaMental, Créteil, France.
  • Brunel L; 2 Department of Adult Psychiatry, Versailles Hospital, Le Chesnay, France.
  • Capdevielle D; 3 HandiRESP Laboratory, EA4047, Health Sciences Department Simone Veil, University of Versailles Saint-Quentin-En-Yvelines, Montigny-le-Bretonneux, France.
  • Chereau I; 1 Fondation FondaMental, Créteil, France.
  • Dubreucq J; 2 Department of Adult Psychiatry, Versailles Hospital, Le Chesnay, France.
  • Faget-Agius C; 3 HandiRESP Laboratory, EA4047, Health Sciences Department Simone Veil, University of Versailles Saint-Quentin-En-Yvelines, Montigny-le-Bretonneux, France.
  • Fond G; 1 Fondation FondaMental, Créteil, France.
  • Leignier S; 4 Strasbourg University Hospital, INSERM U1114, Strasbourg Federation of Translational Psychiatry, University of Strasbourg, Strasbourg, France.
  • Perier CC; 1 Fondation FondaMental, Créteil, France.
  • Richieri R; 5 INSERM U955, Translational Psychiatry Team, Université Paris-Est Créteil (UPEC), AP-HP, DHU Pe-PSY, Department of Adult Psychiatry, Henri Mondor University Hospitals, Créteil, France.
  • Schneider P; 1 Fondation FondaMental, Créteil, France.
  • Schürhoff F; 6 University Department of Adult Psychiatry, La Colombière Hospital, CHU Montpellier, University of Montpellier 1, INSERM 1061, Montpellier, France.
  • Tronche AM; 1 Fondation FondaMental, Créteil, France.
  • Yazbek H; 7 CMP B, Clermont-Ferrand University Hospital, EA 7280, Faculty of Medicine, Auvergne University, Clermont-Ferrand Cedex 1, France.
  • Zinetti-Bertschy A; 1 Fondation FondaMental, Créteil, France.
  • Passerieux C; 1 Fondation FondaMental, Créteil, France.
  • Brunet-Gouet E; 9 Academic Department of Psychiatry (AP-HM), Sainte-Marguerite University Hospital, Marseille, France.
Clin Rehabil ; 33(1): 113-119, 2019 Jan.
Article in En | MEDLINE | ID: mdl-30012064
ABSTRACT

OBJECTIVE:

This study aimed to evaluate the validity of the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale (ECPDS) to discriminate for cognitive impairment in schizophrenia.

DESIGN:

This multicentre cross-sectional study used a validation design with receiver operating characteristic (ROC) curve analysis. SETTINGS The study was undertaken in a French network of seven outward referral centres.

SUBJECTS:

We recruited individuals with clinically stable schizophrenia diagnosed based on the Structured Clinical Interview for assessing Diagnostic and Statistical Manual of Mental Disorders (4th ed., rev.; DSM-IV-R) criteria. MAIN

MEASURES:

The index test for cognitive impairment was ECPDS (independent variable), a 13-item scale completed by a relative of the participant. The reference standard was a standardized test battery that evaluated seven cognitive domains. Cognitive impairment was the dependent variable and was defined as an average z-score more than 1 SD below the normative mean in two or more cognitive domains.

RESULTS:

Overall, 97 patients were included (67 with schizophrenia, 28 with schizoaffective disorder, and 2 with schizophreniform disorder). The mean age was 30.2 (SD 7.7) years, and there were 75 men (77.3%). There were 59 (60.8%) patients with cognitive impairment on the neuropsychological battery, and the mean ECPDS score was 27.3 (SD 7.3). The ROC curve analysis showed that the optimal ECPDS cut-off was 29.5. The area under the curve was 0.77, with 76.3% specificity and 71.1% sensitivity to discriminate against cognitive impairment.

CONCLUSION:

The ECPDS is a valid triage tool for detecting cognitive impairment in schizophrenia, before using an extensive neuropsychological battery, and holds promise for use in everyday clinical practice.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Schizophrenia / Schizophrenic Psychology / Cognitive Dysfunction Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: Schizophrenia / Schizophrenic Psychology / Cognitive Dysfunction Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2019 Type: Article